Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...
These launches belong to what Oelrich called “must-win battles” at Bayer as Xarelto loss of exclusivity reaches “full swing” ...
Chemical company Monsanto — owned by Bayer — was found liable this week by a jury for harm caused to students and parents at ...
Bayer's projected earnings decline and litigation pressures affect its outlook. Find out why BAYRY stock might face ...
In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.
The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...